Surgical Site Infection Market Insight, Epidemiology, and Market Forecast Analysis Report
What is Surgical Site Infection?
Surgical Site Infections (SSIs) are the most common nosocomial infection and frequently cause morbidity and mortality among patients of hospitals.
As per DelveInsight's research, the total Surgical Site Infection Incident cases in the 7MM were 1,323,491 cases in 2018. Moreover, it is observed that males and females are equally affected.
The Surgical Site Infection Market Report provides historical as well as forecasted epidemiological analysis segmented into:
- Total Surgical Procedures
- Number of Surgical Procedures by Type
- Total Surgical Site Infections Incident Cases
- Surgical Site Infections Incidence by Type
To know more, request sample pages of Surgical Site Infection Market Report @ https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
Surgical Site Infection Market Outlook
For most infections, source control is the basic principle of management. In most cases, opening the wound and allowing the pus to drain the following culture collection is sufficient in most superficial Surgical Site Infection cases. The routine use of antibiotics for wounds displaying minimal erythema is not indicated. Five cm of erythema that extends beyond the incision has been suggested as a reasonable threshold for the initiation of systemic antibiotics. The most common organism isolated from superficial Surgical Site Infections is S. aureus, along with others.
The Surgical Site Infection market forecasthas been segmented into two sections, the prophylactic therapy drug market from overall surgical procedures and Surgical Site Infection treatment drug market from the patient pool. Generic antibiotics dominate the prophylactic therapy drug market, and most common drugs include cefazolin, vancomycin, cefuroxime, clindamycin, cefotetan, metronidazole, and gentamicin. On the other hand, the Surgical Site Infection treatment drug market is based on antibiotics such as vancomycin and linezolid (Cardiothoracic/related leg SSI), and tigecycline IV (Abdominal SSI). Due to their easy availability and reach, these drugs have a higher penetration rate in the Surgical Site Infection market, thereby adding up to the total revenue generated.
Surgical Site Infection is a potential complication associated with any type of surgical procedure. Although SSIs are among the most preventable healthcare-associated infections (HAIs), they still represent a significant burden in patient morbidity and mortality and additional costs to health systems and service payers worldwide. For these reasons, Surgical Site Infection prevention has received considerable attention from surgeons and infection control professionals, health care authorities, the media, and the public.
Which are the leading companies in Surgical Site Infection market?
Surgical Site Infection Emerging Therapies Along with Key Players
- XF-73: Destiny Pharma
- D-PLEX100: PolyPid
- Delafloxacin: Menarini Group Pharma
- BTX 1801: Botanix Pharma
- DFA-02: Dr Reddy's Laboratories Ltd.
- Zuragard: Zurex Pharma
And several others.
Request sample pages for more information on Surgical Site Infection Market Trends @ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market